학술논문
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial
Document Type
Article
Author
Source
In: Dermatologic Therapy . (Dermatologic Therapy, March 2022, 35(3))
Subject
Language
English
ISSN
15298019
13960296
13960296